Drugs / Fludarabina
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01969942 | Apr 2013 → Oct 2016 | Ewing sarcoma | University of Louisville | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT00774826 | Dec 2005 → Sep 2010 | follicular lymphoma | Fondazione Italiana Linfomi - ETS | Unknown | Met primary |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fludarabina | “Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,” NCT00774826 ↗ |